EPS Q/Q spoločnosti NeuroVive Pharmaceutical AB
Aká je hodnota metriky EPS Q/Q spoločnosti NeuroVive Pharmaceutical AB?
Hodnota metriky EPS Q/Q spoločnosti NeuroVive Pharmaceutical AB je N/A
Aká je definícia metriky EPS Q/Q?
Štvrťročný rast EPS (Quarterly EPS growth rate) zo štvrťroku na štvrťrok je nárast EPS spoločnosti za posledné štyri štvrťroky v porovnaní s výsledkami z minulých štyroch štvrťrokov.
The earnings per share growth rate is an important factor for judging a company's value. EPS growth rate gives a good picture of the rate at which the company has grown its profitability in respect to the total number of shares. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
Čomu sa venuje spoločnosť NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.